ADMA Biologics
ADMA
13.17
-0.17
-1.27%
ADMA Biologics
US · ADMA
#2705 by market cap
Listed 1970
13.17
-0.17
-1.27%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Cantor Fitzgerald moved from Buy to Hold on 2026-03-25.
Analyst consensus 3 analysts
Buy
Avg price target 16.67 +26.6%
Price target rangecurrent 13.17
Low13.00
Avg16.67
High19.00
Buy 67%
Hold 33%
Sell 0%
Recent ratings (15)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-05 | Cantor Fitzgerald | -- | Hold | 13.00 |
| 2026-11-05 | CCORF | -- | Buy | 19.00 |
| 2026-11-05 | Mizuho Securities | -- | Buy | 18.00 |
| 2026-08-06 | CCORF | -- | Buy | 18.00 |
| 2026-08-05 | Cantor Fitzgerald | -- | Hold | 12.00 |
| 2026-07-15 | Mizuho Securities | -- | Buy | 17.00 |
| 2026-06-14 | CCORF | -- | Buy | 18.00 |
| 2026-06-10 | Raymond James | -- | Buy | 21.00 |
| 2026-05-07 | Mizuho Securities | -- | Buy | 20.00 |
| 2026-05-05 | CCORF | -- | Buy | 18.00 |
| 2026-04-20 | CCORF | -- | Buy | 21.00 |
| 2026-04-13 | Mizuho Securities | -- | Buy | 24.00 |
| 2026-03-25 | Cantor Fitzgerald | -- | Hold | 30.00 |
| 2026-02-25 | Cantor Fitzgerald | -- | Buy | 30.00 |
| 2025-11-05 | Cantor Fitzgerald | -- | Buy | 30.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-03-25 | Cantor Fitzgerald | Buy → Hold | 30.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | After close | ±17.90% | +26.05% (beat) |
| 2026/Q2 | 2026-08-05 | After close | ±11.41% | +8.64% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±14.46% | -15.97% (beat) |
| 2025/Q4 | 2026-02-25 | After close | ±11.89% | -3.19% (in line) |
| 2025/Q3 | 2025-11-05 | After close | ±16.07% | -8.72% (in line) |
| 2025/Q2 | 2025-08-06 | After close | ±15.49% | -9.65% (in line) |
| 2025/Q1 | 2025-05-07 | After close | ±14.34% | -10.21% (in line) |
| 2024/Q4 | 2025-03-03 | After close | ±18.41% | +7.45% (in line) |
| 2024/Q3 | 2024-11-07 | After close | ±17.12% | +14.71% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±24.82% | +30.93% (beat) |
| 2024/Q1 | 2024-05-09 | After close | ±11.40% | +27.13% (beat) |
| 2023/Q4 | 2024-02-28 | After close | ±16.17% | -0.37% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ADMA Biologics discussion 0 comments